KalVista reports Q2 EPS (90c), consensus ($1.06)

Cash, cash equivalents and marketable securities were $122.3M as of October 31, 2022, vs. $166.2M as of April 30, 2022. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses."We made a very difficult decision this quarter in terminating our phase 2 KOMPLETE trial for KVD824, but the safety of patients is of utmost importance to our company," said CEO Andrew Crockett. "We remain committed to providing best-in-class oral treatments for the hereditary angioedema community. We are particularly excited about our recent data for the orally disintegrating tablet formulation of sebetralstat, which will enable people to take a dose without requiring chewing or swallowing. We are also pleased with the progress of our Phase 3 KONFIDENT clinical trial for sebetralstat, which remains on our enrollment target for data in the second half of 2023."